For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Cannabis (medicinal) - Pain (Chronic)
PAD Profile : Cannabis (medicinal) - Pain (Chronic)
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
No drugs returned.
Other Indications
- Lambert-Eaton myasthenic syndrome (LEMS)
- Pain
- Osteoarthritis
- Erectile dysfunction
- Hyperuricaemia and Gout
- Dysphagia
- Low sexual desire in menopausal women
- Psoriasis
- Atopic dermatitis
- Multiple sclerosis
- Duchenne muscular dystrophy
- Multiple sclerosis
- Systemic Lupus Erythematosus
- Inclusion body myositis
- Systemic Lupus Erythematosus
- Duchenne muscular dystrophy
- Systemic Lupus Erythematosus
- Multiple sclerosis
- Short bowel syndrome
- Any paediatric use
- Erectile dysfunction combination therapy
- Children and young people with Epilepsy
- Diabetes Mellitus
- Interface Prescribing Policy (IPP)
- Restless Leg Syndrome
- Narcolepsy
- All
- Atopic dermatitis
- Psoriasis
- Inflammatory bowel disease
- Ulcerative colitis - moderately to severely active
- Migraine (prevention)
- Dry eyes
- Cancer
- Diarrhoea
- Ulcerative colitis - moderately to severely active
- Non-radiographic axial spondyloarthritis
- Photoaggravated dermatoses
- Photodermatoses
- Metabolic disorders
- Insomnia in adults
- Cardiomyopathy
- Epidermolysis bullosa
- Photoaggravated dermatoses
- Psoriasis
- Psoriatic arthritis
- Photodermatoses
- Photodermatoses
- Photoaggravated dermatoses
- Catheter maintenance solutions
- Dry eyes
- Dry eyes
- Dry eyes
- Dry eyes
- Dry eyes
- Dysphagia
- Prurigo nodularis
- Vitamin D deficiency and insufficiency
- Osteoporosis
- Migraine (prevention)
- Pain
- Pustular psoriasis
- Mucus clearance
- Atopic dermatitis
- Alopecia
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Smoking cessation
- Pain
- Homozygous familial hypercholesterolaemia
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Metabolic disorders
- Concious sedation
- Premedication
- post Bariatric surgery
- Erectile dysfunction
- Parkinson's disease
- Myasthenia gravis
Additional Documents
Committee Recommendations
NHS England guidance to support clinicians on the prescribing of cannabis-based products for medicinal use:
The Surrey & North West Sussex Area Prescribing Committee (APC) recommends that Cannabis based medicinal products (CBMP) for chronic pain are given a BLACK traffic light status in line with NICE NG144, which states that these products (nabilone, dronabinol, Tetrahydrocannabinol (THC) & the combination of THC & cannabidiol (Sativex) should not be offered to manage chronic pain in adult patients unless as part of a clinical trial.
The APC concurred that there is likely to be even less evidence available for children and young people, so the recommendation should apply to all ages.
Providers (NHS and non-NHS) will be solely liable for clinical governance, prescribing responsibility and costs of all prescriptions of cannabis-based medicinal products when it is used off-label i.e. outside of its marketing authorisation. Shared care will not be supported for an off-label uses.
Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.